It’s a shame accounting standards setters don’t respect the way knowledge of fixed costs, variable costs, and operating leverage can help investors, so we’re left on our own here. This framework ...

Kiniksa Pharmaceuticals leverages ARCALYST as it is a first-in-class FDA-approved treatment for recurrent pericarditis, driving recurring revenue and strong growth. Q3 FY2025 ARCALYST revenue was $180 ...

Stride, Inc. LRN continues to deliver robust margin growth. In third-quarter fiscal 2025, the company reported a robust performance with adjusted EBITDA rising 40% year over year to a record $168.3 ...